Novo Nordisk Clinches UK Pill Approval and US Medicare Win, but Competition Narrows the Path
Novo Nordisk has pulled off a rare double-catalyst week, securing both a European approval for its oral Wegovy…
Novo Nordisk’s Stock Hinges on ADA Data as US Reimbursement Window Narrows
Novo Nordisk presents CagriSema and zenagamtide data at ADA, while CVS Caremark ends Wegovy’s exclusive formulary status, intensifying…
European Lithium’s Valuation Gap Narrows as Greenland Project Advances
European Lithium’s 12% surge follows Greenland project approval, revealing a valuation gap where its cash and Critical Metals…